Literature DB >> 2495813

Effect of the combination of alinidine and other anti-anginal drugs on heart rate and blood pressure in healthy volunteers.

D W Harron1, A H Deering, M Scott, M McMahon, R G Shanks.   

Abstract

1. Heart rate and blood pressure changes following the administration of alinidine 30 mg alone and in combination with atenolol 25 mg, nifedipine retard 20 mg and glyceryl trinitrate 500 micrograms were investigated in three groups of six healthy male volunteers. 2. Concomitant administration of alinidine and atenolol reduced (P less than 0.05) supine, standing and exercise heart rate when compared with alinidine alone. The maximum reduction in exercise heart rate was 116 +/- 2.4 beats min-1 for the combination vs 129.0 +/- 3.1 beats min-1 for alinidine alone. 3. Supine (3, 4, 8 h) and standing (2 h) systolic BP were also reduced (P less than 0.05) with the alinidine and atenolol combination compared with alinidine alone. Little change occurred in diastolic blood pressure. 4. Alinidine and nifedipine in combination reduced (P less than 0.05) the nifedipine induced increase in heart rate in the supine (2, 4 h) and standing (4 h) position and following exercise (2, 4 h). No further decreases in systolic and diastolic blood pressure occurred with the combination. 5. Alinidine administered 2 h before a glyceryl trinitrate challenge reduced (P less than 0.05) the glyceryl trinitrate induced increase in standing heart rate at all time intervals (1 to 6 min); the maximum reduction occurred at 3 min (105.0 +/- 4.3 (glyceryl trinitrate) vs 86.8 +/- 6.7 beats min-1 (combination]. Systolic blood pressure was further reduced at all time intervals with glyceryl trinitrate taken in the presence of alinidine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495813      PMCID: PMC1379701          DOI: 10.1111/j.1365-2125.1989.tb05331.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

Review 1.  Pharmacology, clinical pharmacology and potential therapeutic uses of the specific bradycardiac agent alinidine.

Authors:  D W Harron; R G Shanks
Journal:  Eur Heart J       Date:  1985-09       Impact factor: 29.983

2.  Alinidine, a new agent which lowers heart rate in patients with angina pectoris.

Authors:  M L Simoons; J Tummers; H van Meurs-van Woezik; R van Domburg
Journal:  Eur Heart J       Date:  1982-12       Impact factor: 29.983

3.  The effects of drugs on the exercise electrocardiogram.

Authors:  M L Simoons; K Balakumaran
Journal:  Cardiology       Date:  1981       Impact factor: 1.869

4.  N-Allyl-derivative of clonidine, a substance with specific bradycardic action at a cardiac site.

Authors:  W Kobinger; C Lillie; L Pichler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-04       Impact factor: 3.000

5.  Cardiovascular actions of N-allyl-clonidine (ST 567), a substance with specific bradycardic action.

Authors:  W Kobinger; C Lillie; L Pichler
Journal:  Eur J Pharmacol       Date:  1979-09-15       Impact factor: 4.432

6.  [Hemodynamic actions on alinidine during exercise in patients with coronary artery disease].

Authors:  H Löllgen; H Just; H Wollschläger; F Kersting
Journal:  Z Kardiol       Date:  1981-05

7.  The effect of alinidine (St 567) on emotionally induced tachycardia in man.

Authors:  J Auböck; H Konzett; E Olbrich
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Relative roles of heart rate and ventricular stroke volume for the regulation of cardiac output during controlled hypotension with sodium nitroprusside in man.

Authors:  M Zimpfer; S Fitzal; M Semsroth
Journal:  Eur J Clin Invest       Date:  1982-02       Impact factor: 4.686

9.  Comparative effects of alinidine and propranolol in ischaemic heart disease.

Authors:  J Schurmans; J Piessens; H Kesteloot; H De Geest
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Alinidine reduces heart-rate without blockade of beta-adrenoceptors.

Authors:  D W Harron; J G Riddell; R G Shanks
Journal:  Lancet       Date:  1981-02-14       Impact factor: 79.321

  10 in total
  1 in total

Review 1.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.